Document is current

Any future updates will be listed below

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

Crossref DOI link: https://doi.org/10.1007/s12032-014-0078-5

Published Online: 2014-06-24

Published Print: 2014-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark